Full Press Release Details
Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom for RDEB
investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB
Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) ("INmune" or the "Company"), a late-stage
biotechnology company focused on inflammation and immunology, will host a webinar on CORDStrom for the treatment of recessive dystrophic
epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET.
session will focus on the latest results from the MissionEB Phase III clinical trial, specifically highlighting the systemic disease-modifying
capabilities of CORDStrom in patients with RDEB
Focus: Beyond Topical Care
current standard-of-care options that are limited to topical wound treatments, CORDStrom is being developed as a systemic, disease-modifying
therapy. The upcoming webinar will spotlight new data demonstrating CORDStrom's impact on key clinical benchmarks in RDEB:
Clinical & Scientific Experts
webinar will feature firsthand clinical observations from the investigators who initiated and ran the MissionEB study in the United Kingdom
to include insights into the systemic nature of the disease and the scientific rationale behind the use of CORDStrom:
register, click here or copy and paste the link below:
is a patent-pending cell medicine comprising aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs)
in suspension for injection or infusion. The CORDStrom platform leverages, among other things, proprietary screening, pooling
and expansion techniques to create off-the-shelf, allogeneic, pooled hucMSCs as medicines to treat complex inflammatory and autoimmune
diseases. CORDStrom products are designed to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured,
potent cellular medicines that can be produced affordably and with repeatable specification. Pooling allows tuning of different CORDStrom
products with different effector functionsdependent upon selected donor characteristics. While the first generation CORDStrom
product is agnostic to disease indication, the platform enables creation of indication-specific products, which can be tuned for optimization
of anti-inflammatory, immunomodulatory, wound healing, and other characteristics.
Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate
immune system to fight disease. INmune Bio has three product platforms: (1) CORDStrom , a proprietary pooled, allogeneic, human
umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive
dystrophic epidermolysis bullosa; (2) XPro , a Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform designed to selectively
neutralize soluble TNF, a key driver of inflammation and innate immune dysfunction; and (3) INKmune , a cell-based medicine designed
to prime a patient's natural killer cells to eliminate minimal residual disease in patients with cancer. To learn more, please
visit www.inmunebio.com.
trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press
release related to the development or commercialization of product candidates and other business and financial matters, including without
limitation, trial results and data, including trial results, timing of key milestones, future plans or expectations, and the prospects
for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are
based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and
circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties.
CORDstrom , XPro1595 (XPro , pegipanermin), and INKmune have either finished clinical trials, are still
in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA),
the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory
body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to produce more drug for
clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research
and development, clinical studies and future product commercialization; and the Company's business, research, product development,
regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail
in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K,
the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K. The Company assumes no obligation
to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Chief Executive Officer
Head of Investor Relations